Diabetes-Induced Reactive Oxygen Species: Mechanism of Their Generation and Role in Renal Injury

Journal of Diabetes Research

Volumn 2017, Issue , 2017, Pages

  Fakhruddin, Selim ^a   Alanazi, Wael ^a   Jackson, Keith E ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; CELL ADHESION MOLECULE; CHEMOKINE; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; VASOACTIVE AGENT;

AUTOPHAGY; DIABETES MELLITUS; DISEASE COURSE; END STAGE RENAL DISEASE; ENDOTHELIUM; GLOMERULAR FILTRATION BARRIER; GLOMERULAR MESANGIAL CELL; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; KIDNEY FAILURE; KIDNEY INJURY; KIDNEY STRUCTURE; MESANGIUM CELL; MICROALBUMINURIA; MITOCHONDRION; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; ULTRAFILTRATION; ANIMAL; DIABETIC NEPHROPATHY; KIDNEY; METABOLISM; PATHOLOGY;

ANIMALS; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; KIDNEY; PODOCYTES; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY;

EID: 85010683524     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2017/8379327     Document Type: Review

References (292)

1. American Diabetes Association, "Diagnosis, classification of diabetes mellitus, " Diabetes Care, vol. 33, no. 1, pp. S62-S69, 2010.
2. Centers for Disease Control, Prevention, National Diabetes Statistics Report: Estimates of Diabetes, Its Burden in the United States, 2014, Department ofHealth andHuman Services, Atlanta, Ga, USA, 2014.
3. Global Status Report on Noncommunicable Diseases 2014, World Health Organization, Geneva, Switzerland, 2012.
4. C. D. Mathers, D. Loncar, "Projections of global mortality, burden of disease from 2002 to 2030, " PLoS Medicine, vol. 3, no. 11, article e442, 2006.
5. Centers for Disease Control, Prevention (CDC), National Chronic Kidney Disease Fact Sheet: General Information, National Estimates on Chronic Kidney Disease in the United States, 2014, US Department of Health, Human Services, Atlanta, Ga, USA, 2014.
6. B.-C. Liu, X. Song, X.-Y. Lu, et al., "High glucose induces podocyte apoptosis by stimulating TRPC6 via elevation of reactive oxygen species, " Biochimica et Biophysica Acta, vol. 1833, no. 6, pp. 1434-1442, 2013.
7. P. Anil Kumar, G. I. Welsh, M. A. Saleem, R. K. Menon, "Molecular, cellular events mediating glomerular podocyte dysfunction, depletion in diabetes mellitus, " Frontiers in Endocrinology, vol. 5, 2014.
8. K. K. Venkat, "Proteinuria, microalbuminuria in adults: significance, evaluation, treatment, " SouthernMedical Journal, vol. 97, no. 10, pp. 969-979, 2004.
9. G. Jarad, J. H. Miner, "Update on the glomerular filtration barrier, " Current Opinion in Nephrology, Hypertension, vol. 18, no. 3, pp. 226-232, 2009.
10. A. L. Sellers, N. Griggs, J. Marmorston, H. C. Goodman, "Filtration, reabsorption of protein by the kidney, " The Journal of experimental medicine, vol. 100, no. 1, pp. 1-10, 1954.
11. G. C. Viberti, D. Mackintosh, R. W. Bilous, J. C. Pickup, H. Keen, "Proteinuria in diabetes mellitus: role of spontaneous, experimental variation of glycemia, " Kidney International, vol. 21, no. 5, pp. 714-720, 1982.
12. A. I. Adler, R. J. Stevens, S. E. Manley, R. W. Bilous, C. A. Cull, R. R. Holman, "Development andprogressionofnephropathy in type 2 diabetes: theUnited Kingdomprospective diabetes study (UKPDS 64), " Kidney International, vol. 63, no. 1, pp. 225-232, 2003.
13. S. P. B. Ramirez, W. McClellan, F. K. Port, S. I.-H. Hsu, "Risk factors for proteinuria in a large, multiracial, Southeast Asian population, " Journal of the American Society of Nephrology, vol. 13, no. 7, pp. 1907-1917, 2002.
14. C. M. Chan, "Hyperlipidaemia in chronic kidney disease, " Annals of the Academy of Medicine Singapore, vol. 34, no. 1, pp. 31-35, 2005.
15. American Diabetes Association, "Standards of medical care for patients with diabetes mellitus. (Posistion statement), " Diabetes Care, vol. 25, supplement 1, pp. S33-S49, 2002.
16. A. S. A. Naderi, R. F. Reilly, "Primary care approach to proteinuria, " Journal of the American Board of Family Medicine, vol. 21, no. 6, pp. 569-574, 2008.
17. P. W. Mathieson, "The cellular basis of albuminuria, " Clinical Science, vol. 107, no. 6, pp. 533-538, 2004.
18. S. M. Bagshaw, R. Bellomo, "Early diagnosis of acute kidney injury, " Current Opinion in Critical Care, vol. 13, no. 6, pp. 638-644, 2007.
19. M. J. Karnovsky, "The ultrastructure of glomerular filtration, " Annual Review of Medicine, vol. 30, pp. 213-224, 1979.
20. A. Remuzzi, G. Remuzzi, "Glomerular perm-selective function, " Kidney International, vol. 45, no. 2, pp. 398-402, 1994.
21. M. P. Bohrer, C. Baylis, H. D. Humes, R. J. Glassock, C. R. Robertson, B. M. Brenner, "Permselectivity of the glomerular capillary wall: facilitated filtration of circulating polycations, " Journal of Clinical Investigation, vol. 61, no. 1, pp. 72-78, 1978.
22. E. L. Bearer, L. Orci, P. Sors, "Endothelial fenestral diaphragms: a quick-freeze, deep-etch study, "TheJournal of Cell Biology, vol. 100, no. 2, pp. 418-428, 1985.
23. B. Haraldsson, J. Nyström, W. M. Deen, "Properties of the glomerular barrier, mechanisms of proteinuria, " Physiological Reviews, vol. 88, no. 2, pp. 451-487, 2008.
24. B. J. Ballermann, R. V. Stan, "Resolved: capillary endothelium is a major contributor to the glomerular filtration barrier, " Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2432-2438, 2007.
25. S. Reitsma, D. W. Slaaf, H. Vink, M. A. M. J. Van Zandvoort, M. G. A. Oude Egbrink, "The endothelial glycocalyx: composition, functions, visualization, " European Journal of Physiology, vol. 454, no. 3, pp. 345-359, 2007.
26. S. Weinbaum, J. M. Tarbell, E. R. Damiano, "The structure, function of the endothelial glycocalyx layer, "Annual Review of Biomedical Engineering, vol. 9, pp. 121-167, 2007.
27. M. J. C. Dane, B. M. Van Den Berg, M. C. Avramut, et al., "Glomerular endothelial surface layer acts as a barrier against albumin filtration, " American Journal of Pathology, vol. 182, no. 5, pp. 1532-1540, 2013.
28. M. Jeansson, B. Haraldsson, "Morphological, functional evidence for an important role of the endothelial cell glycocalyx in the glomerular barrier, " American Journal of Physiology-Renal Physiology, vol. 290, no. 1, pp. F111-F116, 2006.
29. A. Singh, S. C. Satchell, C. R. Neal, E. A. McKenzie, J. E. Tooke, P. W. Mathieson, "Glomerular endothelial glycocalyx constitutes a barrier to protein permeability, " Journal of the American Society of Nephrology, vol. 18, no. 11, pp. 2885-2893, 2007.
30. M. Jeansson, B. Haraldsson, "Glomerular size, charge selectivity in the mouse after exposure to glucosaminoglycandegrading enzymes, " Journal of the American Society of Nephrology, vol. 14, no. 7, pp. 1756-1765, 2003.
31. E. Sawanobori, N. Terada, Y. Fujii, K. Higashida, S. Nakazawa, S. Ohno, "Ultrastructural study of human glomerular capillary loops with igA nephropathy using quick-freezing, deep-etchingmethod, " Histology, Histopathology, vol. 23, no. 3, pp. 297-307, 2008.
32. J. Patrakka, K. Tryggvason, "Molecular make-up of the glomerular filtration barrier, " Biochemical, Biophysical Research Communications, vol. 396, no. 1, pp. 164-169, 2010.
33. M. C. Menon, P. Y. Chuang, C. J. He, "Theglomerular filtration barrier: components, crosstalk, " International Journal of Nephrology, vol. 2012, Article ID 749010, 9 pages, 2012.
34. P. D. Yurchenco, "Basement membranes: cell scaffoldings, signaling platforms, " Cold Spring Harbor Perspectives in Biology, vol. 3, no. 2, Article ID a004911, 2011.
35. S. J. Harvey, J. H. Miner, "Revisiting the glomerular charge barrier in the molecular era, " Current Opinion in Nephrology, Hypertension, vol. 17, no. 4, pp. 393-398, 2008.
36. A. J. Groffen, M. A. Ruegg, H. Dijkman, et al., "Agrin is a major heparan sulfate proteoglycan in the human glomerular basement membrane, " Journal of Histochemistry, Cytochemistry, vol. 46, no. 1, pp. 19-27, 1998.
37. J. A. Jefferson, S. J. Shankland, R. H. Pichler, "Proteinuria in diabetic kidney disease: a mechanistic viewpoint, " Kidney International, vol. 74, no. 1, pp. 22-36, 2008.
38. S. J. Harvey, G. Jarad, J. Cunningham, et al., "Disruption of glomerular basement membrane charge through podocytespecific mutation of agrin does not alter glomerular permselectivity, " American Journal of Pathology, vol. 171, no. 1, pp. 139-152, 2007.
39. T. J. M. Wijnhoven, J. F. M. Lensen, R. G. P. Wismans, et al., "In vivo degradation of heparan sulfates in the glomerular basement membrane does not result in proteinuria, " Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 823-832, 2007.
40. T. J. M. Wijnhoven, J. F. M. Lensen, R. G. P. Wismans, et al., "Removal of heparan sulfate from the glomerular basement membrane blocks protein passage, " Journal of the American Society of Nephrology, vol. 18, no. 12, pp. 3119-3127, 2007.
41. A. Greka, P. Mundel, "Cell biology, pathology of podocytes, " Annual Review of Physiology, vol. 74, pp. 299-323, 2012.
42. J.-L. R. Michaud, C. R. J. Kennedy, "The podocyte in health, disease: insights from the mouse, " Clinical Science, vol. 112, no. 5-6, pp. 325-335, 2007.
43. J. Wartiovaara, L. Ofverstedt, J. Khoshnoodi, et al., "Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography, "The Journal of Clinical Investigation, vol. 114, no. 10, pp. 1475-1483, 2004.
44. M. Gekle, "Renal tubule albumin transport, " Annual Review of Physiology, vol. 67, pp. 573-594, 2005.
45. H. Pavenstädt, W. Kriz, M. Kretzler, "Cell biology of the glomerular podocyte, " Physiological Reviews, vol. 83, no. 1, pp. 253-307, 2003.
46. M. M. Löwik, P. J. Groenen, E. N. Levtchenko, L. A. Monnens, L. P. Van Den Heuvel, "Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis-a review, " European Journal of Pediatrics, vol. 168, no. 11, pp. 1291-1304, 2009.
47. J. D. Stockand, S. C. Sansom, "Glomerular mesangial cells: electrophysiology, regulation of contraction, " Physiological Reviews, vol. 78, no. 3, pp. 723-744, 1998.
48. D. Schlöndorff, B. Banas, "The mesangial cell revisited: no cell is an island, " Journal of the American Society of Nephrology, vol. 20, no. 6, pp. 1179-1187, 2009.
49. P. Leveén, M. Pekny, S. Gebre-Medhin, B. Swolin, E. Larsson, C. Betsholtz, "Mice deficient for PDGF B show renal, cardiovascular, hematological abnormalities, " Genes, Development, vol. 8, no. 16, pp. 1875-1887, 1994.
50. J. Lee, N. Koo, D. B. Min, "Reactive oxygen species, aging, antioxidative nutraceuticals, " Comprehensive Reviews in Food Science, Food Safety, vol. 3, no. 1, pp. 21-33, 2004.
51. Y. Taniyama, K. K. Griendling, "Reactive oxygen species in the vasculature:molecular, cellularmechanisms, " Hypertension, vol. 42, no. 6, pp. 1075-1081, 2003.
52. J. S. Johansen, A. K. Harris, D. J. Rychly, A. Ergul, "Oxidative stress, the use of antioxidants in diabetes: linking basic science to clinical pratice, " Cardiovascular Diabetology, vol. 4, article no. 5, 2005.
53. J. F. Turrens, "Mitochondrial formation of reactive oxygen species, " Journal of Physiology, vol. 552, no. 2, pp. 335-344, 2003.
54. Y. Gorin, K. Block, J. Hernandez, et al., "Nox4NAD(P)H oxidase mediates hypertrophy, fibronectin expression in the diabetic kidney, " Journal of Biological Chemistry, vol. 280, no. 47, pp. 39616-39626, 2005.
55. M. Satoh, S. Fujimoto, Y. Haruna, et al., "NAD(P)H oxidase, uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy, " American Journal of Physiology: Renal Physiology, vol. 288, no. 6, pp. F1144-F1152, 2005.
56. H. Cheng, H. Wang, X. Fan, P. Paueksakon, R. C. Harris, "Improvement of endothelial nitric oxide synthase activity retards the progression of diabetic nephropathy in db/db mice, " Kidney International, vol. 82, no. 11, pp. 1176-1183, 2012.
57. C. Rüster, T. Bondeva, S. Franke, M. Förster, G. Wolf, "Advanced glycation end-products induce cell cycle arrest, hypertrophy in podocytes, " Nephrology Dialysis Transplantation, vol. 23, no. 7, pp. 2179-2191, 2008.
58. S. Munusamy, L. A. MacMillan-Crow, "Mitochondrial superoxide plays a crucial role in the development of mitochondrial dysfunction during high glucose exposure in rat renal proximal tubular cells, " Free Radical Biology, Medicine, vol. 46, no. 8, pp. 1149-1157, 2009.
59. K. Shahzad, F. Bock, W. Dong, et al., "Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy, " Kidney International, vol. 87, no. 1, pp. 74-84, 2015.
60. V. Thallas-Bonke, J. C. Jha, S. P. Gray, et al., "Nox-4 deletion reduces oxidative stress, injury by PKC-associated mechanisms in diabetic nephropathy, " Physiological Reports, vol. 2, no. 11, Article ID e12192, 2014.
61. K. Bedard, K.-H. Krause, "The NOX family of ROSgeneratingNADPHoxidases: physiology, pathophysiology, " Physiological Reviews, vol. 87, no. 1, pp. 245-313, 2007.
62. K. K. Griendling, C. A. Minieri, J. D. Ollerenshaw, R. W. Alexander, "Angiotensin II stimulates NADH, NADPH oxidase activity in cultured vascular smooth muscle cells, " Circulation Research, vol. 74, no. 6, pp. 1141-1148, 1994.
63. T. Chabrashvili, A. Tojo, M. L. Onozato, et al., "Expression, cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney, " Hypertension, vol. 39, no. 2 I, pp. 269-274, 2002.
64. J.-M. Li, A. M. Shah, "Intracellular localization, preassembly of the NADPH oxidase complex in cultured endothelial cells, " Journal of Biological Chemistry, vol. 277, no. 22, pp. 19952-19960, 2002.
65. B. Lasségue, D. Sorescu, K. Szöcs, et al., "Novel gp91 homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation, redoxsensitive signaling pathways, " Circulation Research, vol. 88, pp. 888-894, 2001.
66. P. L. Hordijk, "Regulation of NADPH oxidases: the role of Rac proteins, " Circulation Research, vol. 98, no. 4, pp. 453-462, 2006.
67. R. E. Clempus, K. K. Griendling, "Reactive oxygen species signaling in vascular smooth muscle cells, " Cardiovascular Research, vol. 71, no. 2, pp. 216-225, 2006.
68. M.-H. Paclet, S. Berthier, L. Kuhn, J. Garin, F. Morel, "Regulation of phagocyte NADPH oxidase activity: identification of two cytochrome b558 activation states, " The FASEB Journal, vol. 21, no. 4, pp. 1244-1255, 2007.
69. C. Y. Han, T. Umemoto, M. Omer, et al., "NADPH oxidasederived reactive oxygen species increases expression of monocyte chemotactic factor genes in cultured adipocytes, " Journal of Biological Chemistry, vol. 287, no. 13, pp. 10379-10393, 2012.
70. M. Chopra, K. Kaul, J. Tarr, R. Choudhury, E. M. Kohner, R. Chibber, "Oxidative stress in diabetic neuropathy: source of reactive oxygen species, " Endocrinology Studies, vol. 2, no. 2, 2012.
71. K. Sakai, K. Matsumoto, T. Nishikawa, et al., "Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic-cells, " Biochemical, Biophysical Research Communications, vol. 300, no. 1, pp. 216-222, 2003.
72. T. Nishikawa, D. Edelstein, X. L. Du, et al., "Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage, " Nature, vol. 404, no. 6779, pp. 787-790, 2000.
73. S. R. Pieczenik, J. Neustadt, "Mitochondrial dysfunction, molecular pathways of disease, " Experimental, Molecular Pathology, vol. 83, no. 1, pp. 84-92, 2007.
74. G. Lenaz, "The mitochondrial production of reactive oxygen species: mechanisms, implications in human pathology, " IUBMB Life, vol. 52, no. 3-5, pp. 159-164, 2001.
75. Q. Chen, E. J. Vazquez, S. Moghaddas, C. L. Hoppel, E. J. Lesnefsky, "Production of reactive oxygen species by mitochondria: central role of complex III, " Journal of Biological Chemistry, vol. 278, no. 38, pp. 36027-36031, 2003.
76. J. F. Turrens, A. Boveris, "Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria, " Biochemical Journal, vol. 191, no. 2, pp. 421-427, 1980.
77. K. Green, M. D. Brand, M. P. Murphy, "Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes, " Diabetes, vol. 53, no. 1, pp. S110-S118, 2004.
78. M. P. Murphy, "How mitochondria produce reactive oxygen species, " Biochemical Journal, vol. 417, no. 1, pp. 1-13, 2009.
79. M. Watabe, T. Nakaki, "Mitochondrial complex I inhibitor rotenone-elicited dopamine redistribution from vesicles to cytosol in human dopaminergic SH-SY5Y cells, " Journal of Pharmacology, ExperimentalTherapeutics, vol. 323, no. 2, pp. 499-507, 2007.
80. W. J. H. Koopman, S. Verkaart, H.-J. Visch, et al., "Inhibition of complex I of the electron transport chain causesO2-mediated mitochondrial outgrowth, " American Journal of Physiology-Cell Physiology, vol. 288, no. 6, pp. C1440-C1450, 2005.
81. A. Anedda, E. Rial, M. M. González-Barroso, "Metformin induces oxidative stress in white adipocytes, raises uncoupling protein 2 levels, " Journal of Endocrinology, vol. 199, no. 1, pp. 33-40, 2008.
82. R. Fato, C. Bergamini, M. Bortolus, et al., "Differential effects of mitochondrial complex I inhibitors on production of reactive oxygen species, " Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1787, no. 5, pp. 384-392, 2009.
83. K. Sakai, K. Matsumoto, T. Nishikawa, et al., "Mitochondrial reactive oxygen species reduce insulin secretion by pancreatic-cells, " Biochemical, Biophysical Research Communications, vol. 300, no. 1, pp. 216-222, 2003.
84. A. Panov, S. Dikalov, N. Shalbuyeva, R. Hemendinger, J. T. Greenamyre, J. Rosenfeld, "Species-, tissue-specific relationships between mitochondrial permeability transition, generation of ROS in brain, liver mitochondria of rats, mice, " American Journal of Physiology-Cell Physiology, vol. 292, no. 2, pp. C708-C718, 2007.
85. A. Panov, S. Dikalov, N. Shalbuyeva, G. Taylor, T. Sherer, J. T. Greenamyre, "Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication, "The Journal of Biological Chemistry, vol. 280, no. 51, pp. 42026-42035, 2005.
86. M. A. Aon, S. Cortassa, E. Marbán, B. O'Rourke, "Synchronized whole cell oscillations in mitochondrial metabolism triggered by a local release of reactive oxygen species in cardiac myocytes, " The Journal of Biological Chemistry, vol. 278, no. 45, pp. 44735-44744, 2003.
87. D. F. Stowe, A. K. S. Camara, "Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial, cell function, " Antioxidants & Redox Signaling, vol. 11, no. 6, pp. 1373-1414, 2009.
88. S. Dröse, "Differential effects of complex II on mitochondrial ROS production, their relation to cardioprotective pre-, postconditioning, " Biochimica et Biophysica Acta-Bioenergetics, vol. 1827, no. 5, pp. 578-587, 2013.
89. A. Anderson, A. Bowman, S. J. Boulton, P. Manning, M. A. Birch-Machin, "A role for human mitochondrial complex II in the production of reactive oxygen species in human skin, " Redox Biology, vol. 2, pp. 1016-1022, 2014.
90. J. M. Forbes, M. T. Coughlan, M. E. Cooper, "Oxidative stress as amajor culprit in kidney disease in diabetes, " Diabetes, vol. 57, no. 6, pp. 1446-1454, 2008.
91. S. S. Korshunov, V. P. Skulachev, A. A. Starkov, "High protonic potential actuates a mechanism of production of reactive oxygen species inmitochondria, " FEBS Letters, vol. 416, no. 1, pp. 15-18, 1997.
92. Y. Liu, G. Fiskum, D. Schubert, "Generation of reactive oxygen species by the mitochondrial electron transport chain, " Journal of Neurochemistry, vol. 80, no. 5, pp. 780-787, 2002.
93. A. Boveris, N. Oshino, B. Chance, "The cellular production of hydrogen peroxide, " Biochemical Journal, vol. 128, no. 3, pp. 617-630, 1972.
94. H. Raza, S. K. Prabu, A. John, N. G. Avadhani, "Impaired mitochondrial respiratory functions, oxidative stress in streptozotocin-induced diabetic rats, " International Journal of Molecular Sciences, vol. 12, no. 5, pp. 3133-3147, 2011.
95. A. Stirban, T. Gawlowski, M. Roden, "Vascular effects of advanced glycation endproducts: clinical effects, molecular mechanisms, " Molecular Metabolism, vol. 3, no. 2, pp. 94-108, 2014.
96. A. Goldin, J. A. Beckman, A. M. Schmidt, M. A. Creager, "Advanced glycation end products: sparking the development of diabetic vascular injury, " Circulation, vol. 114, no. 6, pp. 597-605, 2006.
97. M. Koch, S. Chitayat, B. M. Dattilo, et al., "Structural basis for ligand recognition, activation of RAGE, " Structure, vol. 18, no. 10, pp. 1342-1352, 2010.
98. D. Xu, J. M. Kyriakis, "Phosphatidylinositol 3-kinasedependent activation of renal mesangial cell Ki-Ras, ERK by advanced glycation end products, " Journal of Biological Chemistry, vol. 278, no. 41, pp. 39349-39355, 2003.
99. T. M. Wendt, N. Tanji, J. Guo, et al., "RAGE drives the development of glomerulosclerosis, implicates podocyte activation in the pathogenesis of diabetic nephropathy, " American Journal of Pathology, vol. 162, no. 4, pp. 1123-1137, 2003.
100. A. L. Y. Tan, J. M. Forbes, M. E. Cooper, "AGE, RAGE, ROS in diabetic nephropathy, " Seminars in Nephrology, vol. 27, no. 2, pp. 130-143, 2007.
101. E. Linden, W. Cai, J. C. He, et al., "Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation, " Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 691-698, 2008.
102. N. Lin, H. Zhang, Q. Su, "Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress, " Diabetes, Metabolism, vol. 38, no. 3, pp. 250-257, 2012.
103. P. Y. Chuang, Q. Yu, W. Fang, J. Uribarri, J. C. He, "Advanced glycation endproducts induce podocyte apoptosis by activation of the FOXO4 transcription factor, " Kidney International, vol. 72, no. 8, pp. 965-976, 2007.
104. M.-P. Wautier, O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, J.-L. Wautier, "Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE, " American Journal of Physiology-Endocrinology, Metabolism, vol. 280, no. 5, pp. E685-E694, 2001.
105. W. K. Alderton, C. E. Cooper, R. G. Knowles, "Nitric oxide synthases: structure, function, inhibition, " Biochemical Journal, vol. 357, no. 3, pp. 593-615, 2001.
106. M. E. Murphy, H. Sies, "Reversible conversion of nitroxyl anion to nitric oxide by superoxide dismutase, " Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 23, pp. 10860-10864, 1991.
107. U. Förstermann, T. Münzel, "Endothelial nitric oxide synthase in vascular disease: from marvel to menace, " Circulation, vol. 113, no. 13, pp. 1708-1714, 2006.
108. C. F. B. Witteveen, J. Giovanelli, S. Kaufman, "Reduction of quinonoid dihydrobiopterin to tetrahydrobiopterin by nitric oxide synthase, " Journal of Biological Chemistry, vol. 271, no. 8, pp. 4143-4147, 1996.
109. B. Thöny, G. Auerbach, N. Blau, "Tetrahydrobiopterin biosynthesis, regeneration, functions, " Biochemical Journal, vol. 347, no. 1, pp. 1-16, 2000.
110. T. J. Guzik, S. Mussa, D. Gastaldi, et al., "Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase, endothelial nitric oxide synthase, " Circulation, vol. 105, no. 14, pp. 1656-1662, 2002.
111. Y. Xia, L. J. Roman, B. S. S. Masters, J. L. Zweier, "Inducible nitric-oxide synthase generates superoxide from the reductase domain, " The Journal of Biological Chemistry, vol. 273, no. 35, pp. 22635-22639, 1998.
112. S. Pou, W. S. Pou, D. S. Bredt, S. H. Snyder, G. M. Resen, "Generation of superoxide by purified brain nitric oxide synthase, " The Journal of Biological Chemistry, vol. 267, no. 34, pp. 24173-24176, 1992.
113. G. M. Rosen, P. Tsai, J. Weaver, et al., "The role of tetrahydrobiopterin in the regulation of neuronal nitric-oxide synthasegenerated superoxide, " Journal of Biological Chemistry, vol. 277, no. 43, pp. 40275-40280, 2002.
114. M. Inoue, E. F. Sato, M. Nishikawa, et al., "Mitochondrial generation of reactive oxygen species, its role in aerobic life, "CurrentMedicinal Chemistry, vol. 10, no. 23, pp. 2495-2505, 2003.
115. Y. B. Y. Sun, X. Qu, X. Zhang, G. Caruana, J. F. Bertram, J. Li, "Glomerular endothelial cell injury, damage precedes that of podocytes in adriamycin-induced nephropathy, " PLOS ONE, vol. 8, no. 1, Article ID e55027, 2013.
116. K. Sison, V. Eremina, H. Baelde, et al., "Glomerular structure, function require paracrine, not autocrine, VEGF-VEGFR-2 signaling, " Journal of the American Society of Nephrology, vol. 21, no. 10, pp. 1691-1701, 2010.
117. D. R. Abrahamson, B. G. Hudson, L. Stroganova, D.-B. Borza, P. L. St John, "Cellular origins of type IV collagen networks in developing glomeruli, " Journal of the American Society of Nephrology, vol. 20, no. 7, pp. 1471-1479, 2009.
118. R. Moseley, R. J. Waddington, G. Embery, "Degradation of glycosaminoglycans by reactive oxygen species derived from stimulated polymorphonuclear leukocytes, " Biochimica et Biophysica Acta, vol. 1362, no. 2-3, pp. 221-231, 1997.
119. C. B. S. Henry, B. R. Duling, "TNF-increases entry of macromolecules into luminal endothelial cell glycocalyx, " American Journal of Physiology-Heart, Circulatory Physiology, vol. 279, no. 6, pp. H2815-H2823, 2000.
120. A. Singh, R. D. Ramnath, R. R. Foster, et al., "Reactive oxygen species modulate the barrier function of the human glomerular endothelial glycocalyx, " PLOS ONE, vol. 8, no. 2, Article ID e55852, 2013.
121. A. Singh, V. Fridén, I. Dasgupta, et al., "High glucose causes dysfunction of the human glomerular endothelial glycocalyx, " American Journal of Physiology: Renal Physiology, vol. 300, no. 1, pp. F40-F48, 2011.
122. R. F. Van Golen, T. M. Van Gulik, M. Heger, "Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury, " Free Radical Biology, Medicine, vol. 52, no. 8, pp. 1382-1402, 2012.
123. H. Kolárová, B. Ambruzová, L. S. vihálková, et al., "Modulation of endothelial glycocalyx structure under inflammatory conditions, " Meidiators of Inflammation, vol. 2014, Article ID 694312, 17 pages, 2014.
124. E. A. Jaimes, P. Hua, R.-X. Tian, L. Raij, "Human glomerular endothelium: interplay among glucose, free fatty acids, angiotensin II, oxidative stress, " American Journal of Physiology: Renal Physiology, vol. 298, no. 1, pp. F125-F132, 2010.
125. S. Savard, P. Lavoie, C. Villeneuve, M. Agharazii, M. Lebel, R. Larivire, "ENOS gene delivery prevents hypertension, reduces renal failure, injury in ratswith reducedrenalmass, " Nephrology Dialysis Transplantation, vol. 27, no. 6, pp. 2182-2190, 2012.
126. T. Nakagawa, K. Tanabe, B. P. Croker, et al., "Endothelial dysfunction as a potential contributor in diabetic nephropathy, " Nature Reviews Nephrology, vol. 7, no. 1, pp. 36-44, 2011.
127. C. J. I. Raats, M. A. H. Bakker, J. Van Den Born, J. H. M. Berden, "Hydroxyl radicals depolymerize glomerular heparan sulfate in vitro, in experimental nephrotic syndrome, " Journal of Biological Chemistry, vol. 272, no. 42, pp. 26734-26741, 1997.
128. C. J. I. Raats, J. VanDenBorn, J. H. M. Berden, "Glomerular heparan sulfate alterations: mechanisms, relevance for proteinuria, " Kidney International, vol. 57, no. 2, pp. 385-400, 2000.
129. N. Kashihara, Y. Watanabe, H. Makino, E. I. Wallner, Y. S. Kanwar, "Selective decreased de novo synthesis of glomerular proteoglycans under the influence of reactive oxygen species, " Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 14, pp. 6309-6313, 1992.
130. S. J. Klebanoff, M. G. Kinsella, T. N. Wight, "Degradation of endothelial cell matrix heparan sulfate proteoglycan by elastase, the myeloperoxidase-H2O2-chloride system, " The American Journal of Pathology, vol. 143, no. 3, pp. 907-917, 1993.
131. J. H. Suh, J. H. Miner, "The glomerular basementmembrane as a barrier to albumin, " Nature Reviews Nephrology, vol. 9, no. 8, pp. 470-477, 2013.
132. E. I. Mohamed, N. M. Fahmi, S. M. El Kholy, S. M. Sallam, "Effects of reactive oxygen species on in vitro filtration of water, albumin across glomerular basement membrane, " International Journal of Biomedical Science, vol. 2, no. 2, pp. 85-100, 2006.
133. D. Kerjaschki, D. J. Sharkey, M. G. Farquhar, "Identification, characterization of podocalyxin-themajor sialoprotein of the renal glomerular epithelial cell, " Journal of Cell Biology, vol. 98, no. 4, pp. 1591-1596, 1984.
134. K. Matsui, S. Breiteneder-Geleff, A. Soleiman, H. Kowalski, D. Kerjaschki, "Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes, " Nephrology Dialysis Transplantation, vol. 14, no. 1, pp. 9-11, 1999.
135. T. W. Huang, J. C. Langlois, "Podoendin. A new cell surface protein of the podocyte, endothelium, " Journal of Experimental Medicine, vol. 162, no. 1, pp. 245-267, 1985.
136. K. Susztak, A. C. Raff, M. Schiffer, E. P. Böttinger, "Glucoseinduced reactive oxygen species cause apoptosis of podocytes, podocyte depletion at the onset of diabetic nephropathy, " Diabetes, vol. 55, no. 1, pp. 225-233, 2006.
137. S. J. Shankland, "The podocyte's response to injury: role in proteinuria, glomerulosclerosis, " Kidney International, vol. 69, no. 12, pp. 2131-2147, 2006.
138. H. Liapis, P. Romagnani, H.-J. Anders, "New insights into the pathology of podocyte loss: mitotic catastrophe, " American Journal of Pathology, vol. 183, no. 5, pp. 1364-1374, 2013.
139. S. Greiber, T. Münzel, S. Kästner, B. Müller, P. Schollmeyer, H. Pavenstädt, "NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate, " Kidney International, vol. 53, no. 3, pp. 654-663, 1998.
140. A. Whaley-Connell, J. Habibi, R. Nistala, et al., "Attenuation of NADPH oxidase activation, glomerular filtration barrier remodeling with statin treatment, " Hypertension, vol. 51, no. 2, pp. 474-480, 2008.
141. C. Zhu, S. Huang, Y. Yuan, et al., "Mitochondrial dysfunction mediates aldosterone-induced podocyte damage: a therapeutic target of PPAR, " American Journal of Pathology, vol. 178, no. 5, pp. 2020-2031, 2011.
142. L. Gu, S. Hagiwara, Q. Fan, et al., "Role of receptor for advanced glycation end-products, signalling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes, " Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 299-313, 2006.
143. A. Piwkowska, D. Rogacka, M. Jankowski, M. H. Dominiczak, J. K. Stepínski, S. Angielski, "Metformin induces suppression of NAD(P)H oxidase activity in podocytes, " Biochemical, Biophysical Research Communications, vol. 393, no. 2, pp. 268-273, 2010.
144. J. Toyonaga, K. Tsuruya, H. Ikeda, et al., "Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production, " Nephrology Dialysis Transplantation, vol. 26, no. 8, pp. 2475-2484, 2011.
145. I. Loeffer, G. Wolf, "Transforming growth factor-, the progression of renal disease, " Nephrology Dialysis Transplantation, vol. 29, supplement 1, pp. i37-i45, 2014.
146. M. Schiffer, M. Bitzer, I. S. D. Roberts, et al., "Apoptosis in podocytes induced by TGF-, Smad7, " Journal of Clinical Investigation, vol. 108, no. 6, pp. 807-816, 2001.
147. S. C. Lee, S. H. Han, J. J. Li, et al., "Inductionof heme oxygenase-1 protects against podocyte apoptosis under diabetic conditions, " Kidney International, vol. 76, no. 8, pp. 838-848, 2009.
148. M. C. Iglesias-De La Cruz, P. Ruiz-Torres, J. Alcaḿ, et al., "Hydrogen peroxide increases extracellular matrix mRNA through TGF-in human mesangial cells, " Kidney International, vol. 59, no. 1, pp. 87-95, 2001.
149. J. H. Oh, H. Ha, M. R. Yu, H. B. Lee, "Sequential effects of high glucose on mesangial cell transforming growth factor-1, fibronectin synthesis, " Kidney International, vol. 54, no. 6, pp. 1872-1878, 1998.
150. H. B. Lee, M.-R. Yu, Y. Yang, Z. Jiang, H. Ha, "Reactive oxygen species-regulated signaling pathways in diabetic nephropathy, " Journal of theAmericanSociety ofNephrology, vol. 14, no. 8, S3, pp. S241-S245, 2003.
151. C. D. Bondi, N. Manickam, D. Y. Lee, et al., "NAD(P)H oxidase mediates TGF-1-induced activation of kidneymyofibroblasts, " Journal of the American Society of Nephrology, vol. 21, no. 1, pp. 93-102, 2010.
152. M. Jain, S. Rivera, E. A. Monclus, et al., "Mitochondrial reactive oxygen species regulate transforming growth factor-signaling, " TheJournal of Biological Chemistry, vol. 288, no. 2, pp. 770-777, 2013.
153. G. Wolf, S. Chen, F. N. Ziyadeh, "Fromthe periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy, " Diabetes, vol. 54, no. 6, pp. 1626-1634, 2005.
154. P. V. Kitsiou, A. K. Tzinia, W. G. Stetler-Stevenson, et al., "Glucose-induced changes in integrins andmatrix-related functions in cultured human glomerular epithelial cells, " American Journal of Physiology-Renal Physiology, vol. 284, no. 4, pp. F671-F679, 2003.
155. M. F. Bek, M. Bayer, B. Müller, et al., "Expression, function of C/EBP homology protein (GADD153) in podocytes, " The American Journal of Pathology, vol. 168, no. 1, pp. 20-32, 2006.
156. N. Sachs, M. Kreft, M. A. Van Den Bergh Weerman, et al., "Kidney failure in mice lacking the tetraspanin CD151, " The Journal of Cell Biology, vol. 175, no. 1, pp. 33-39, 2006.
157. A. T. Petermann, R. Krofft, M. Blonski, et al., "Podocytes that detach in experimental membranous nephropathy are viable, " Kidney International, vol. 64, no. 4, pp. 1222-1231, 2003.
158. T. Nakamura, C. Ushiyama, S. Suzuki, et al., "Urinary excretion of podocytes in patients with diabetic nephropathy, " Nephrology Dialysis Transplantation, vol. 15, no. 9, pp. 1379-1383, 2000.
159. J. J. Li, S. J. Kwak, D. S. Jung, et al., "Podocyte biology in diabetic nephropathy, " Kidney International, vol. 72, no. 106, pp. S36-S42, 2007.
160. J. F. do Nascimento, L. H. Canani, F. Gerchman, et al., "Messenger RNA levels of podocyte-associated proteins in subjects with different degrees of glucose tolerance with or without nephropathy, " BMC Nephrology, vol. 14, article 214, 2013.
161. J. H. Koh, E. S. Lee, M. Hyun, et al., "Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model, " International Journal of Endocrinology, vol. 2014, Article ID 397307, 11 pages, 2014.
162. F. Bonnet, M. E. Cooper, H. Kawachi, T. J. Allen, G. Boner, Z. Cao, "Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes, hypertension, " Diabetologia, vol. 44, no. 7, pp. 874-877, 2001.
163. C.-X. Zheng, Z.-H. Chen, C.-H. Zeng, W.-S. Qin, L.-S. Li, Z.-H. Liu, "Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo, in vitro, " Kidney International, vol. 74, no. 5, pp. 596-612, 2008.
164. X. Lan, P. Rai, N. Chandel, et al., "Morphine induces albuminuria by compromising podocyte integrity, " PLoSONE, vol. 8, no. 3, Article ID e55748, 2013.
165. T. B. Huber, B. Hartleben, J. Kim, et al., "Nephrin, CD2AP associate with phosphoinositide 3-OH kinase, stimulate AKT-dependent signaling, "Molecular, Cellular Biology, vol. 23, no. 14, pp. 4917-4928, 2003.
166. A. Lan, J. Du, "Potential role of Akt signaling in chronic kidney disease, "NephrologyDialysis Transplantation, vol. 30, no. 3, pp. 385-394, 2015.
167. G. Manda, A.-I. Checherita, M. V. Comanescu, M. E. Hinescu, "Redox signaling in diabetic nephropathy: hypertrophy versus death choices in mesangial cells, podocytes, " Mediators of Inflammation, vol. 2015, Article ID 604208, 13 pages, 2015.
168. H. E. Yoon, S. J. Kim, S. J. Kim, S. Chung, S. J. Shin, "Tempol attenuates renal fibrosis in micewith unilateral ureteral obstruction: the role of PI3K-Akt-FoxO3a signaling, " Journal of Korean Medical Science, vol. 29, no. 2, pp. 230-237, 2014.
169. S.-X. Guo, Q. Fang, C.-G. You, et al., "Effects of hydrogenrich saline on early acute kidney injury in severely burned rats by suppressing oxidative stress induced apoptosis, inflammation, " Journal of Translational Medicine, vol. 13, article 183, 2015.
170. S. Turdi, Q. Li, F. L. Lopez, J. Ren, "Catalase alleviates cardiomyocyte dysfunction in diabetes: role of Akt, Forkhead transcriptional factor, silent information regulator 2, " Life Sciences, vol. 81, no. 11, pp. 895-905, 2007.
171. J. F. Ndisang, S. Tiwari, "Mechanisms by which heme oxygenase rescue renal dysfunction in obesity, " Redox Biology, vol. 2, pp. 1029-1037, 2014.
172. K. Sharma, S. RamachandraRao, G. Qiu, et al., "Adiponectin regulates albuminuria, podocyte function in mice, " The Journal of Clinical Investigation, vol. 118, no. 5, pp. 1645-1656, 2008.
173. A. Terman, B. Gustafsson, U. T. Brunk, "Autophagy, organelles, ageing, " Journal of Pathology, vol. 211, no. 2, pp. 134-143, 2007.
174. L. Fang, Y. Zhou, H. Cao, et al., "Autophagy attenuates diabetic glomerular damage through protection of hyperglycemiainduced podocyte injury, " PLOS ONE, vol. 8, no. 4, Article ID e60546, 2013.
175. A. Tagawa, M. Yasuda, S. Kume, et al., "Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy, " Diabetes, vol. 65, no. 3, pp. 755-767, 2016.
176. K. Yamahara, M. Yasuda, S. Kume, D. Koya, H. Maegawa, T. Uzu, "The role of autophagy in the pathogenesis of diabetic nephropathy, " Journal of Diabetes Research, vol. 2013, Article ID 193757, 9 pages, 2013.
177. M. Gödel, B. Hartleben, N. Herbach, et al., "Role of mTOR in podocyte function, diabetic nephropathy in humans, mice, " Journal of Clinical Investigation, vol. 121, no. 6, pp. 2197-2209, 2011.
178. Y. Ding, M. E. Choi, "Autophagy in diabetic nephropathy, " Journal of Endocrinology, vol. 224, no. 1, pp. R15-R30, 2015.
179. D. P. Cinà, T. Onay, A. Paltoo, et al., "Inhibition of MTOR disrupts autophagic flux in podocytes, " Journal of the American Society of Nephrology, vol. 23, no. 3, pp. 412-420, 2012.
180. D. Thomasova, H.-J. Anders, "Cell cycle control in the kidney, " Nephrology Dialysis Transplantation, vol. 30, no. 10, pp. 1622-1630, 2015.
181. C. B. Marshall, S. J. Shankland, "Cell cycle, glomerular disease: a minireview, " Nephron-Experimental Nephrology, vol. 102, no. 2, pp. e39-e48, 2006.
182. V. Vallon, K. Richter, R. C. Blantz, S. Thomson, H. Osswald, "Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption, " Journal of the American Society of Nephrology, vol. 10, no. 12, pp. 2569-2576, 1999.
183. P. Persson, P. Hansell, F. Palm, "Tubular reabsorption, diabetes-induced glomerular hyperfiltration, " Acta Physiologica, vol. 200, no. 1, pp. 3-10, 2010.
184. R. Faulhaber-Walter, L. Chen, M. Oppermann, et al., "Lack of A1 adenosine receptors augments diabetic hyperfiltration, glomerular injury, " Journal of the American Society of Nephrology, vol. 19, no. 4, pp. 722-730, 2008.
185. S. Kiritoshi, T. Nishikawa, K. Sonoda, et al., "Reactive oxygen species from mitochondria induce cyclooxygenase-2 gene expression in human mesangial cells: potential role in diabetic nephropathy, " Diabetes, vol. 52, no. 10, pp. 2570-2577, 2003.
186. N. Bank, "Mechanisms of diabetic hyperfiltration, " Kidney International, vol. 40, no. 4, pp. 792-807, 1991.
187. B. Teng, M. Duong, I. Tossidou, X. Yu, M. Schiffer, "Role of protein kinase C in podocytes, development of glomerular damage in diabetic nephropathy, " Frontiers in Endocrinology, vol. 5, article 179, 2014.
188. Y. Ohshiro, Y. Lee, G. L. King, "Mechanism of diabetic nephropathy: role of protein kinase-C activation, " Advanced Studies in Medicine, vol. 5, no. 1A, pp. S10-S19, 2005.
189. H. Konishi, M. Tanaka, Y. Takemura, et al., "Activation of protein kinase C by tyrosine phosphorylation in response to H2O2, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11233-11237, 1997.
190. Z.-G. Xu, D.-R. Ryu, T.-H. Yoo, et al., "P-Cadherin is decreased in diabetic glomeruli, in glucose-stimulated podocytes in vivo, in vitro studies, " Nephrology Dialysis Transplantation, vol. 20, no. 3, pp. 524-531, 2005.
191. A. B. Sanz, M. D. Sanchez-Niño, A. M. Ramos, et al., "NF-B in renal inflammation, " Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1254-1262, 2010.
192. L. M. Pedruzzi, M. B. Stockler-Pinto, M. Leite Jr., D. Mafra, "Nrf2-keap1 system versus NF-B: the good, the evil in chronic kidney disease" Biochimie, vol. 94, no. 12, pp. 2461-2466, 2012.
193. M. J. Morgan, Z.-G. Liu, "Crosstalk of reactive oxygen species, NF-B signaling, " Cell Research, vol. 21, no. 1, pp. 103-115, 2011.
194. M. Ding, X. Shi, Y. Lu, et al., "Induction of activator protein-1 through reactive oxygen species by crystalline silica in JB6 cells, " The Journal of Biological Chemistry, vol. 276, no. 12, pp. 9108-9114, 2001.
195. Y. Zhang, F. Peng, B. Gao, A. J. Ingram, J. C. Krepinsky, "High glucose-induced RhoA activation requires caveolae, PKC1-mediated ROS generation, " American Journal of Physiology-Renal Physiology, vol. 302, no. 1, pp. 159-172, 2012.
196. C. Weigert, U. Sauer, K. Brodbeck, A. Pfeiffer, H. U. Häring, E. D. Schleicher, "AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-1 promoter in mesangial cells, " Journal of the American Society of Nephrology, vol. 11, no. 11, pp. 2007-2016, 2000.
197. V. Vallon, S. C. Thomson, "Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney, " Annual Review of Physiology, vol. 74, pp. 351-375, 2012.
198. T. Isoe, Y. Makino, K. Mizumoto, et al., "High glucose activates HIF-1-mediated signal transduction in glomerular mesangial cells through a carbohydrate response element binding protein, " Kidney International, vol. 78, no. 1, pp. 48-59, 2010.
199. T.-H. Chen, J.-F. Wang, P. Chan, H.-M. Lee, "Angiotensin II stimulates hypoxia-inducible factor 1 accumulation in glomerular mesangial cells, " Annals of the New York Academy of Sciences, vol. 1042, pp. 286-293, 2005.
200. V. H. Haase, "Hypoxia-inducible factor signaling in the development of kidney fibrosis, " Fibrogenesis & Tissue Repair, vol. 5, supplement 1, article S16, 2012.
201. J. Wada, H. Makino, "Inflammation, the pathogenesis of diabetic nephropathy, " Clinical Science, vol. 124, no. 3, pp. 139-152, 2013.
202. L. Jiang, L. Xu, Y. Song, et al., "Calmodulin-dependent protein kinase II/cAMP response element-binding protein/Wnt/-catenin signaling cascade regulates angiotensin II-induced podocyte injury, Albuminuria, " Journal of Biological Chemistry, vol. 288, no. 32, pp. 23368-23379, 2013.
203. P. M. Garcá-Garcá, M. A. Getino-Melián, V. Doḿnguez-Pimentel, J. F. Navarro-González, "Inflammation in diabetic kidney disease, " World Journal of Diabetes, vol. 5, no. 4, pp. 431-443, 2014.
204. C. Sassy-Prigent, D. Heudes, C. Mandet, et al., "Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats, " Diabetes, vol. 49, no. 3, pp. 466-475, 2000.
205. A. K. H. Lim, G. H. Tesch, "Inflammation in diabetic nephropathy, " Mediators of Inflammation, vol. 2012, Article ID 146154, 12 pages, 2012.
206. J. F. Navarro-González, C. Mora-Fernández, "The role of inflammatory cytokines in diabetic nephropathy, " Journal of the American Society ofNephrology, vol. 19, no. 3, pp. 433-442, 2008.
207. N. Choudhary, R. S. Ahlawat, "Interleukin-6, C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, microalbuminuria, " Iranian Journal of Kidney Diseases, vol. 2, no. 2, pp. 72-79, 2008.
208. S. Shelbaya, H. Amer, S. Seddik, et al., "Study of the role of interleukin-6, highly sensitive C-reactive protein in diabetic nephropathy in type 1 diabetic patients, " European Review for Medical, Pharmacological Sciences, vol. 16, no. 2, pp. 176-182, 2012.
209. H. Okamura, H. Tsutsui, T. Komatsu, et al., "Cloning of a new cytokine that induces IFN-production by T cells, " Nature, vol. 378, no. 6552, pp. 88-90, 1995.
210. S.-M. Dai, H. Matsuno, H. Nakamura, K. Nishioka, K. Yudoh, "Interleukin-18 enhances monocyte tumor necrosis factor , interleukin-1 production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis, " Arthritis, Rheumatism, vol. 50, no. 2, pp. 432-443, 2004.
211. R. J. L. Stuyt, M. G. Netea, T. B. H. Geijtenbeek, B. J. Kullberg, C. A. Dinarello, J. W. M. Van Der Meer, "Selective regulation of intercellular adhesion molecule-1 expression by interleukin-18, interleukin-12 on human monocytes, " Immunology, vol. 110, no. 3, pp. 329-334, 2003.
212. E. Mariño, J. E. Cardier, "Differential effect of IL-18 on endothelial cell apoptosis mediated by TNF-, Fas (CD95), " Cytokine, vol. 22, no. 5, pp. 142-148, 2003.
213. M. Schwarz, M. Wahl, K. Resch, H. H. Radeke, "IFN induces functional chemokine receptor expression in human mesangial cells, " Clinical, Experimental Immunology, vol. 128, no. 2, pp. 285-294, 2002.
214. Y. Moriwaki, T. Yamamoto, Y. Shibutani, et al., "Elevated levels of interleukin-18, tumor necrosis factor-in serum of patients with type 2 diabetesmellitus: relationship with diabetic nephropathy, " Metabolism: Clinical, Experimental, vol. 52, no. 5, pp. 605-608, 2003.
215. A. Nakamura, K. Shikata, M. Hiramatsu, et al., "Serum interleukin-18 levels are associated with nephropathy, atherosclerosis in Japanese patients with type 2 diabetes, " Diabetes Care, vol. 28, no. 12, pp. 2890-2895, 2005.
216. S. Araki, M. Haneda, D. Koya, et al., "Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study, " Diabetologia, vol. 50, no. 4, pp. 867-873, 2007.
217. T. Nakamura, M. Fukui, I. Ebihara, et al., "mRNA expression of growth factors in glomeruli from diabetic rats, " Diabetes, vol. 42, no. 3, pp. 450-456, 1993.
218. X. Dong, S. Swaminathan, L. A. Bachman, A. J. Croatt, K. A. Nath, M. D. Griffin, "Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemiareperfusion injury, " Kidney International, vol. 71, no. 7, pp. 619-628, 2007.
219. A. M. Jevnikar, D. C. Brennan, G. G. Singer, et al., "Stimulated kidney tubular epithelial cells expressmembrane associated, secreted TNF, " Kidney International, vol. 40, no. 2, pp. 203-211, 1991.
220. T. J. Neale, B. M. Ruger, H. Macaulay, et al., "Tumor necrosis factor-is expressed by glomerular visceral epithelial cells in human membranous nephropathy, " The American Journal of Pathology, vol. 146, no. 6, pp. 1444-1454, 1995.
221. H. H. Radeke, B. Meier, N. Topley, J. Flöge, G. G. Habermehl, K. Resch, "Interleukin 1-, tumor necrosis factor-induce oxygen radical production in mesangial cells, " Kidney International, vol. 37, no. 2, pp. 767-775, 1990.
222. L. Baud, J. Perez, G. Friedlander, R. Ardaillou, "Tumor necrosis factor stimulates prostaglandin production, cyclic AMP levels in rat cultured mesangial cells, " FEBS Letters, vol. 239, no. 1, pp. 50-54, 1988.
223. B. Wójciak-Stothard, A. Entwistle, R. Garg, A. J. Ridley, "Regulation of TNF-induced reorganization of the actin cytoskeleton, cell-cell junctions by Rho, Rac, Cdc42 in human endothelial cells, " Journal of Cellular Physiology, vol. 176, no. 1, pp. 150-165, 1998.
224. S. M. Laster, J. G. Wood, L. R. Gooding, "Tumor necrosis factor can induce both apoptic, necrotic forms of cell lysis, " Journal of Immunology, vol. 141, no. 8, pp. 2629-2634, 1988.
225. T. Bertani, M. Abbate, C. Zoja, et al., "Tumor necrosis factor induces glomerular damage in the rabbit, "TheAmerican Journal of Pathology, vol. 134, no. 2, pp. 419-430, 1989.
226. J. F. Navarro, F. J. Milena, C. Mora, et al., "Tumor necrosis factor-gene expression in diabetic nephropathy: relationship with urinary albumin excretion, effect of angiotensin-converting enzyme inhibition, " Kidney International, vol. 68, supplement 99, pp. S98-S102, 2005.
227. J. F. Navarro, F. J. Milena, C. Mora, C. León, J. Garcá, "Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition, pentoxifylline administration, " American Journal of Nephrology, vol. 26, no. 6, pp. 562-570, 2006.
228. T. Wada, J. W. Pippen, Y. Terada, S. J. Shankland, "The cyclin-dependent kinase inhibitor p21 is required for TGF-1-induced podocyte apoptosis, " Kidney International, vol. 68, no. 4, pp. 1618-1629, 2005.
229. S. J. Shankland, J. Floege, S. E. Thomas, et al., "Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo, " Kidney International, vol. 52, no. 2, pp. 404-413, 1997.
230. C. J. Kuan, M. Al-Douahji, S. J. Shankland, "The cyclin kinase inhibitor p211, 1 is increased in experimental diabetic nephropathy: potential role in glomerular hypertrophy, " Journal of the American Society of Nephrology, vol. 9, no. 6, pp. 986-993, 1998.
231. G. Gruden, P. C. Perin, G. Camussi, "Insight on the pathogenesis of diabetic nephropathy fromthe study of podocyte, mesangial cell biology, " Current Diabetes Reviews, vol. 1, no. 1, pp. 27-40, 2005.
232. G. Wolf, F. N. Ziyadeh, "Cellular andmolecularmechanisms of proteinuria in diabetic nephropathy, " Nephron-Physiology, vol. 106, no. 2, pp. p26-p31, 2007.
233. M. Khamaisi, B. F. Schrijvers, A. S. de Vriese, I. Raz, A. Flyvbjerg, "The emerging role of VEGF in diabetic kidney disease, " Nephrology Dialysis Transplantation, vol. 18, no. 8, pp. 1427-1430, 2003.
234. K. Iijima, N. Yoshikawa, D. T. Connolly, H. Nakamura, "Human mesangial cells, peripheral blood mononuclear cells produce vascular permeability factor, " Kidney International, vol. 44, no. 5, pp. 959-966, 1993.
235. D. R. Cha, Y. S. Kang, S. Y. Han, et al., "Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats, " Journal of Endocrinology, vol. 183, no. 1, pp. 183-194, 2004.
236. M. E. Cooper, D. Vranes, S. Youssef, et al., "Increased renal expression of vascular endothelial growth factor (VEGF), its receptor VEGFR-2 in experimental diabetes, " Diabetes, vol. 48, no. 11, pp. 2229-2239, 1999.
237. S. Hoshi, Y. Shu, F. Yoshida, et al., "Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats, " Laboratory Investigation, vol. 82, no. 1, pp. 25-35, 2002.
238. E.-Y. Lee, C. H. Chung, J. H. Kim, H.-J. Joung, S. Y. Hong, "Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes, " Nephrology Dialysis Transplantation, vol. 21, no. 6, pp. 1496-1503, 2006.
239. T. Eleftheriadis, G. Antoniadi, G. Pissas, V. Liakopoulos, I. Stefanidis, "The renal endothelium in diabetic nephropathy, " Renal Failure, vol. 35, no. 4, pp. 592-599, 2013.
240. A. S. De Vriese, R. G. Tilton, M. Elger, C. C. Stephan, W. Kriz, N. H. Lameire, "Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes, " Journal of theAmerican Society of Nephrology, vol. 12, no. 5, pp. 993-1000, 2001.
241. B. F. Schrijvers, A. Flyvbjerg, R. G. Tilton, N. H. Lameire, A. S. De Vriese, "A neutralizing VEGF antibody prevents glomerular hypertrophy in amodel of obese type 2 diabetes, the Zucker diabetic fatty rat, " Nephrology Dialysis Transplantation, vol. 21, no. 2, pp. 324-329, 2006.
242. A. Flyvbjerg, F. Dagnæs-Hansen, A. S. De Vriese, B. F. Schrijvers, R. G. Tilton, R. Rasch, "Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody, " Diabetes, vol. 51, no. 10, pp. 3090-3094, 2002.
243. C.-H. Ku, K. E. White, A. D. Cas, et al., "Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice, " Diabetes, vol. 57, no. 10, pp. 2824-2833, 2008.
244. S. H. Sung, F. N. Ziyadeh, A. Wang, P. E. Pyagay, Y. S. Kanwar, S. Chen, "Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice, " Journal of the American Society ofNephrology, vol. 17, no. 11, pp. 3093-3104, 2006.
245. Y. Yamamoto, Y. Maeshima, H. Kitayama, et al., "Tumstatin peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy, " Diabetes, vol. 53, no. 7, pp. 1831-1840, 2004.
246. K. Ichinose, Y. Maeshima, Y. Yamamoto, et al., "Antiangiogenic endostatin peptide ameliorates renal alterations in the early of a type 1 diabetic nephropathy model, " Diabetes, vol. 54, no. 10, pp. 2891-2903, 2005.
247. J. J. Cha, Y. S. Kang, Y. Y. Hyun, et al., "Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats, " Life Sciences, vol. 92, no. 23, pp. 1118-1124, 2013.
248. V. Eremina, J. A. Jefferson, J. Kowalewska, et al., "VEGF inhibition, renal thrombotic microangiopathy, " The New England Journal ofMedicine, vol. 358, no. 11, pp. 1129-1136, 2008.
249. X. Zhu, S. Wu, W. L. Dahut, C. R. Parikh, "Risks of proteinuria, hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review, meta-analysis, " American Journal of Kidney Diseases, vol. 49, no. 2, pp. 186-193, 2007.
250. A. Mima, W. Qi, G. L. King, "Implications of treatment that target protective mechanisms against diabetic nephropathy, " Seminars in Nephrology, vol. 32, no. 5, pp. 471-478, 2012.
251. S. Oltean, Y. Qiu, J. K. Ferguson, et al., "Vascular endothelial growth factor-A165b is protective, restores endothelial glycocalyx in diabetic nephropathy, " Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1889-1904, 2015.
252. M. R. Duncan, K. S. Frazier, S. Abramson, et al., "Connective tissue growth factor mediates transforming growth factor-induced collagen synthesis: down-regulation by cAMP, " FASEB Journal, vol. 13, no. 13, pp. 1774-1786, 1999.
253. N. A. Wahab, B. S. Weston, T. Roberts, R. M. Mason, "Connective tissue growth factor, regulation of the mesangial cell cycle: Role in cellular hypertrophy, " Journal of the American Society of Nephrology, vol. 13, no. 10, pp. 2437-2445, 2002.
254. S. E. Thomson, S. V. McLennan, P. D. Kirwan, et al., "Renal connective tissue growth factor correlates with glomerular basement membrane thickness, prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy, " Journal of Diabetes, Its Complications, vol. 22, no. 4, pp. 284-294, 2008.
255. L. R. James, C. Le, H. Doherty, H.-S. Kim, N. Maeda, "Connective tissue growth factor (CTGF) expressionmodulates response to high glucose, " PLoS ONE, vol. 8, no. 8, Article ID e70441, 2013.
256. H. Yokoi, M. Mukoyama, K. Mori, et al., "Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice, " Kidney International, vol. 73, no. 4, pp. 446-455, 2008.
257. E. Sánchez-López, S. Rayego, R. Rodrigues-Déz, et al., "CTGF promotes inflammatory cell infiltration of the renal interstitium by activatingNF-B, " Journal of theAmericanSociety ofNephrology, vol. 20, no. 7, pp. 1513-1526, 2009.
258. S. V. McLennan, X. Y. Wang, V. Moreno, D. K. Yue, S. M. Twigg, "Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy, " Endocrinology, vol. 145, no. 12, pp. 5646-5655, 2004.
259. J. Floege, F. Eitner, C. E. Alpers, "A new look at plateletderived growth factor in renal disease, " Journal of the American Society of Nephrology, vol. 19, no. 1, pp. 12-23, 2008.
260. P. Boor, T. Ostendorf, J. Floege, "PDGF, the progression of renal disease, " Nephrology Dialysis Transplantation, vol. 29, supplement 1, pp. i45-i54, 2014.
261. D. E. Staunton, S. D. Marlin, C. Stratowa, M. L. Dustin, T. A. Springer, "Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin, integrin supergene families, " Cell, vol. 52, no. 6, pp. 925-933, 1988.
262. K. Shikata, H. Makino, "Microinflammation in the pathogenesis of diabetic nephropathy, " Journal of Diabetes Investigation, vol. 4, no. 2, pp. 142-149, 2013.
263. C. W. Park, J. H. Kim, J. W. Lee, et al., "High glucose-induced intercellular adhesionmolecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa Bdependent, " Diabetologia, vol. 43, no. 12, pp. 1544-1553, 2000.
264. H. Sugimoto, K. Shikata, K. Hirata, et al., "Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation, " Diabetes, vol. 46, no. 12, pp. 2075-2081, 1997.
265. T. M. Coimbra, U. Janssen, H. J. Gröne, et al., "Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes, " Kidney International, vol. 57, no. 1, pp. 167-182, 2000.
266. F. Y. Chow, D. J. Nikolic-Paterson, E. Ozols, R. C. Atkins, G. H. Tesch, "Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice, " Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1711-1722, 2005.
267. S. Okada, K. Shikata, M. Matsuda, et al., "Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes, " Diabetes, vol. 52, no. 10, pp. 2586-2593, 2003.
268. Y. Hosokawa, I. Hosokawa, K. Ozaki, H. Nakae, T. Matsuo, "Cytokines differentially regulate ICAM-1, VCAM-1 expression on human gingival fibroblasts, " Clinical, Experimental Immunology, vol. 144, no. 3, pp. 494-502, 2006.
269. E. Di Marco, S. P. Gray, K. Jandeleit-Dahm, "Diabetes alters activation, repression of pro-, anti-inflammatory signaling pathways in the vasculature, " Frontiers in Endocrinology, vol. 4, article 68, 2013.
270. T. Wada, K. Furuichi, N. Sakai, et al., "Up-regulation ofmonocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy, " Kidney International, vol. 58, no. 4, pp. 1492-1499, 2000.
271. B. Amann, R. Tinzmann, B. Angelkort, "ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1, " Diabetes Care, vol. 26, no. 8, pp. 2421-2425, 2003.
272. F. Y. Chow, D. J. Nikolic-Paterson, E. Ozols, R. C. Atkins, B. J. Rollin, G. H. Tesch, "Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice, " Kidney International, vol. 69, no. 1, pp. 73-80, 2006.
273. A. C. K. Chung, H. Y. Lan, "Chemokines in renal injury, " Journal of theAmerican Society of Nephrology, vol. 22, no. 5, pp. 802-809, 2011.
274. J. F. Ndisang, A. Jadhav, M. Mishra, "The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflammation, ameliorates diabetic nephropathy in zucker diabetic fatty rats, " PLoS ONE, vol. 9, no. 1, Article ID e87936, 2014.
275. G. Ding, K. Reddy, A. A. Kapasi, et al., "Angiotensin II induces apoptosis in rat glomerular epithelial cells, " American Journal of Physiology-Renal Physiology, vol. 283, no. 1, pp. F173-F180, 2002.
276. S. Blanco, J. Bonet, D. López, I. Casas, R. Romero, "ACE inhibitors improve nephrin expression in Zucker rats with glomerulosclerosis, " Kidney International, vol. 67, supplement 93, pp. S10-S14, 2005.
277. S. Kagami, W. A. Border, D. E. Miller, N. A. Noble, "Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-expression in rat glomerular mesangial cells, " The Journal of Clinical Investigation, vol. 93, no. 6, pp. 2431-2437, 1994.
278. J. D. Ahn, R. Morishita, Y. Kaneda, et al., "Transcription factor decoy for AP-1 reduces mesangial cell proliferation, extracellular matrix production in vitro, in vivo, " Gene Therapy, vol. 11, no. 11, pp. 916-923, 2004.
279. A. Sachse, G. Wolf, "Angiotensin II-induced reactive oxygen species, the kidney, " Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2439-2446, 2007.
280. K. N. Campbell, L. Raij, P. Mundel, "Role of angiotensin II in the development of nephropathy, podocytopathy of diabetes, " Current Diabetes Reviews, vol. 7, no. 1, pp. 3-7, 2011.
281. C. Cabello-Verrugio, M. J. Acuña, M. G. Morales, A. Becerra, F. Simon, E. Brandan, "Fibrotic response induced by angiotensin-II requires NAD(P)H oxidase-induced reactive oxygen species (ROS) in skeletal muscle cells, " Biochemical, Biophysical Research Communications, vol. 410, no. 3, pp. 665-670, 2011.
282. J. M. Sasser, J. C. Sullivan, J. L. Hobbs, et al., "Endothelin A receptor blockade reduces diabetic renal injury via an antiinflammatory mechanism, " Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 143-154, 2007.
283. C. Reichetzeder, O. Tsuprykov, B. Hocher, "Endothelin receptor antagonists in clinical research-lessons learned from preclinical, clinical kidney studies, " Life Sciences, vol. 118, no. 2, pp. 141-148, 2014.
284. M. S. Simonson, F. Ismail-Beigi, "Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine, cytokine autocrine signaling loop, " The Journal of Biological Chemistry, vol. 286, no. 13, pp. 11003-11008, 2011.
285. W. Kriz, N. Gretz, K. V. Lemley, "Progression of glomerular diseases: is the podocyte the culprit" Kidney International, vol. 54, no. 3, pp. 687-697, 1998.
286. A. A. Eddy, "Molecular basis of renal fibrosis, " PediatricNephrology, vol. 15, no. 3-4, pp. 290-301, 2000.
287. A. A. Eddy, "Proteinuria, interstitial injury, " Nephrology Dialysis Transplantation, vol. 19, no. 2, pp. 277-281, 2004.
288. A. A. Eddy, "Interstitial nephritis induced by protein-overload proteinuria, " American Journal of Pathology, vol. 135, no. 4, pp. 719-733, 1989.
289. W. Kriz, H. Hosser, B. Hähnel, N. Gretz, A. P. Provoost, "From segmental glomerulosclerosis to total nephron degeneration, interstitial fibrosis: a histopathological study in rat models, human gomerulopathies, " Nephrology Dialysis Transplantation, vol. 13, no. 11, pp. 2781-2798, 1998.
290. C. Thomas, L. Thomas, "Renal failure-measuring the glomerular filtration rate, " Deutsches Arzteblatt International, vol. 106, no. 51-52, pp. 849-854, 2009.
291. R. Das, S. Xu, X. Quan, et al., "Upregulation of mitochondrial Nox4 mediates TGF-induced apoptosis in cultured mouse podocytes, " American Journal of Physiology: Renal Physiology, vol. 306, no. 2, pp. F155-F167, 2014.
292. S. Yaddanapudi, M. M. Altintas, A. D. Kistler, et al., "CD2AP inmouse, human podocytes controls a proteolytic program that regulates cytoskeletal structure, cellular survival, " The Journal of Clinical Investigation, vol. 121, no. 10, pp. 3965-3980, 2011.